WO2002065834A8 - Novel formulations of carvedilol - Google Patents

Novel formulations of carvedilol

Info

Publication number
WO2002065834A8
WO2002065834A8 PCT/US2001/050872 US0150872W WO02065834A8 WO 2002065834 A8 WO2002065834 A8 WO 2002065834A8 US 0150872 W US0150872 W US 0150872W WO 02065834 A8 WO02065834 A8 WO 02065834A8
Authority
WO
Grant status
Application
Patent type
Prior art keywords
carvedilol
novel formulations
formulations
novel
angina
Prior art date
Application number
PCT/US2001/050872
Other languages
French (fr)
Other versions
WO2002065834A3 (en )
WO2002065834A2 (en )
Inventor
Vlassios Andronis
Kimberly A Lamey
Choon K Oh
Original Assignee
Smithkline Beecham Corp
Vlassios Andronis
Kimberly A Lamey
Choon K Oh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Abstract

This invention relates to a novel formulations comprising carvedilol and methods of using these formulations to treat hypertension, congestive heart failure and angina.
PCT/US2001/050872 2000-10-24 2001-10-23 Novel formulations of carvedilol WO2002065834A8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US24291100 true 2000-10-24 2000-10-24
US60/242,911 2000-10-24

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA 2426811 CA2426811A1 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
JP2002565411A JP2004518734A (en) 2000-10-24 2001-10-23 New prescriptions in the carvedilol
EP20010273804 EP1335707A4 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol
US10415671 US20040019096A1 (en) 2001-10-23 2001-10-23 Novel formulations of carvedilol

Publications (3)

Publication Number Publication Date
WO2002065834A2 true WO2002065834A2 (en) 2002-08-29
WO2002065834A3 true WO2002065834A3 (en) 2002-10-03
WO2002065834A8 true true WO2002065834A8 (en) 2003-06-26

Family

ID=22916614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050872 WO2002065834A8 (en) 2000-10-24 2001-10-23 Novel formulations of carvedilol

Country Status (4)

Country Link
EP (1) EP1335707A4 (en)
JP (1) JP2004518734A (en)
CA (1) CA2426811A1 (en)
WO (1) WO2002065834A8 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
DK1429734T3 (en) * 2001-09-21 2008-05-13 Egalet As Solid dispersions of carvedilol for the Controlled Release
US20040234602A1 (en) * 2001-09-21 2004-11-25 Gina Fischer Polymer release system
DE602004025159D1 (en) 2003-03-26 2010-03-04 Egalet As Matrix preparations for the controlled administration of drugs
WO2004041252A1 (en) 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
ES2662903T3 (en) * 2003-11-25 2018-04-10 Smithkline Beecham (Cork) Limited carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and methods of treatment or administration
WO2005051325A3 (en) * 2003-11-25 2005-08-11 Matthew D Burke Carvedilol compositions methods of treatment and delivery
CA2599219C (en) 2005-02-25 2011-09-20 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease
DK1928431T3 (en) * 2005-08-26 2009-04-20 Egis Gyogyszergyar Nyilvanosan Pharmaceutically "controlled release" pharmaceutical preparation containing carvedilol
CN102218077A (en) 2006-08-01 2011-10-19 普里克萨斯医药股份有限公司 Use of poloxamer for the prevention and/or treatment of heart failure
WO2008102192A3 (en) * 2007-02-23 2009-04-09 Krisztina Abraham Controlled release pharmaceutical compositions
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
US8372387B2 (en) 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
FR2936709B1 (en) * 2008-10-02 2012-05-11 Ethypharm Sa Tablets alcohol-resistant.
CN102740838B (en) * 2009-09-29 2015-07-01 东生华制药股份有限公司 Controlled release formulation of carvedilol

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19637082A1 (en) * 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Rapidly disintegrating pellets
DE69826113T2 (en) * 1997-03-11 2005-01-20 Arakis Ltd., Saffron Walden R- and S- enantiomeric separate parts dosage forms containing
DE19816036A1 (en) * 1998-04-09 1999-10-14 Roche Diagnostics Gmbh Production of pharmaceutical preparations with high disintegration rate containing difficultly soluble active ingredient, e.g. carvedilol
KR100336090B1 (en) * 1998-06-27 2002-05-27 윤승원 Solid dispersed preparation of poorly water-soluble drug containing oil, fatty acid or mixture thereof
DE19833119A1 (en) * 1998-07-23 2000-01-27 Roche Diagnostics Gmbh Storage-stable injectable solution of vasodilator and beta blocker Carvedilol contains buffer, organic solvent, antioxidant and complexing agent
ES2195638T3 (en) * 1998-11-27 2003-12-01 Hoffmann La Roche Preparations of pharmaceutical combinations in solid dosage form containing carvedilol and hydrochlorothiazide that.
CA2392085A1 (en) * 1999-11-15 2001-05-25 Smithkline Beecham Corporation Carvedilol methanesulfonate
DE60105996T2 (en) * 2000-04-03 2006-03-09 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
US9375428B2 (en) 2003-03-26 2016-06-28 Egalet Ltd. Morphine controlled release system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en) 2009-02-06 2016-06-07 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en) 2009-06-24 2015-05-05 Egalet Ltd. Formulations and methods for the controlled release of active drug substances
US9549899B2 (en) 2012-07-06 2017-01-24 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release

Also Published As

Publication number Publication date Type
EP1335707A2 (en) 2003-08-20 application
EP1335707A4 (en) 2005-07-06 application
JP2004518734A (en) 2004-06-24 application
CA2426811A1 (en) 2002-08-29 application
WO2002065834A3 (en) 2002-10-03 application
WO2002065834A2 (en) 2002-08-29 application

Similar Documents

Publication Publication Date Title
WO2003029209A3 (en) Chemical compounds
WO2004007520A3 (en) Methods and compositions for preventing oxidative degradation of proteins
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
WO2005065645A3 (en) Donepezil formulations
WO2003020212A3 (en) Treatment for central nervous system disorders
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
WO2001023362A3 (en) Rate-controlled particles
WO2001068868A2 (en) Alpha(iii) subunit of prolyl 4-hydroxylase
WO2002074978A3 (en) Nucleic acid shuffling
WO2002079492A8 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2002020013A3 (en) A method for treating allergies using substituted pyrazoles
WO2002049413A3 (en) Thrombopoietin mimetics
RU2004113091A (en) A method and apparatus for controlling the outer loop power line communication multichannel obrabotnoy
USD473995S1 (en) Garment top
WO2003070749A3 (en) Self-assembly of peptide-amphiphile nanofibers under physiological conditions
USD470789S1 (en) Necklace
WO2001057194A3 (en) Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO1999057325A3 (en) Enzymes mixture
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
EP1124296A3 (en) Multifrequency laser system
RU2003110575A (en) Pyrazole derivatives useful as inhibitors roteinkinazy
RU2005112728A (en) Stabilized coffee aroma that contains no stabilizer
RU2003105825A (en) Methods for performing authentication for the Universal Mobile Telecommunications System (UMTS, umts) messages using Session Initiation Protocol (sip)
WO2002077267A3 (en) Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
EP0726072A3 (en) Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2426811

Country of ref document: CA

Ref document number: 10415671

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002565411

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001273804

Country of ref document: EP

CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 35/2002 UNDER (22) REPLACE "19 OCTOBER 2001 (19.10.2001)" BY "23 OCTOBER 2001 (23.10.2001)

CFP Corrected version of a pamphlet front page
WWP Wipo information: published in national office

Ref document number: 2001273804

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001273804

Country of ref document: EP